Translational Research in Developing Skin Microbiome Therapeutics
Sarasota, FL, September 20, 2017– Dr. Nicholas Monsul – Chairman/Founder of Quorum Innovations will deliver a key address to the Annual Microbiome Summit today in Vienna, Austria. Dr. Monsul will demonstrate the capabilities to modulate the skin microbiota and effectively restore microbiome ecology by stimulating the innate immune response. He will present how Quorum has developed an effective drug platform that has delivered microbiome therapeutics that modulate the skin microbiome by increasing the growth of commensal bacteria while inhibiting the growth of methicillin-resistant Staphylococcus aureus (MRSA).
Learn more about Quorum Innovations at https://www.quoruminnovations.com
Quorum Innovations’ patents include the compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Quorum’s inventions provide pharmaceutical and cosmetic compositions, and the methods comprising a strain of Lactobacillus fermentum bacterium native to human microbiota and capable of growing in biofilm phenotype.
Quorum Innovations ProBiomic™ technology can currently be found in Quorum Innovation’s skin care line – BioEsse (www.bioesseprobiotics.com)